Xeris Biopharma Holdings, Inc.

( )
XERS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. 0.79%245.431.5%$930.12m
MRNAModerna, Inc. 0.44%142.810.0%$790.53m
REGNRegeneron Pharmaceuticals, Inc. 0.54%597.622.6%$505.40m
VRTXVertex Pharmaceuticals, Inc. 1.51%280.351.9%$504.03m
GILDGilead Sciences, Inc. 0.43%62.481.0%$502.90m
NVAXNovavax, Inc. 1.55%51.8575.7%$413.51m
ILMNIllumina, Inc. -0.53%186.433.3%$349.53m
SNSSSunesis Pharmaceuticals, Inc. 6.29%3.550.7%$248.16m
BIIBBiogen, Inc. 1.34%205.231.8%$246.04m
BNTXBioNTech SE 1.55%141.980.0%$168.44m
CRSPCRISPR Therapeutics AG -0.44%63.000.6%$166.23m
BMRNBioMarin Pharmaceutical, Inc. 0.93%83.924.2%$122.49m
EXASEXACT Sciences Corp. -1.29%40.5817.7%$95.83m
TECHBio-Techne Corp. 0.72%348.504.5%$93.10m
IOVAIovance Biotherapeutics, Inc. -0.82%10.890.0%$92.14m

Company Profile

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.